Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease ; volume:27 ; number:7 ; day:14 ; month:6 ; year:2013 ; pages:573-582 ; date:7.2013
CNS drugs ; 27, Heft 7 (14.6.2013), 573-582, 7.2013
- Urheber
-
Rive, Benoît
Gauthier, Serge
Costello, Sophie
Marre, Caroline
François, Clément
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-013-0074-x
- URN
-
urn:nbn:de:101:1-2019101101243547456769
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rive, Benoît
- Gauthier, Serge
- Costello, Sophie
- Marre, Caroline
- François, Clément
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Genetics of Alzheimer’s disease
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Molecular subtypes of Alzheimer’s disease
Zulassungserweiterung - Memantine auch bei moderater Alzheimer-Demenz
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
Evaluating genomic signatures of aging in brain tissue as it relates to Alzheimer’s disease
Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Genetics of Alzheimer’s disease
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Molecular subtypes of Alzheimer’s disease
Zulassungserweiterung - Memantine auch bei moderater Alzheimer-Demenz
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
Evaluating genomic signatures of aging in brain tissue as it relates to Alzheimer’s disease
Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Genetics of Alzheimer’s disease
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
Molecular subtypes of Alzheimer’s disease
Zulassungserweiterung - Memantine auch bei moderater Alzheimer-Demenz
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
Evaluating genomic signatures of aging in brain tissue as it relates to Alzheimer’s disease